Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "EDS"

1380 News Found

Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’
News | December 20, 2024

Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’

The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery


Sterling Biotech to start world’s first precision fermentation-based dairy protein factory in Gujarat
News | December 20, 2024

Sterling Biotech to start world’s first precision fermentation-based dairy protein factory in Gujarat

This facility marks a significant milestone in transforming the global food industr


Granules India FDA approval for ADHD treatment
Drug Approval | December 17, 2024

Granules India FDA approval for ADHD treatment


Rusan Pharma achieves GMP approvals from TGA (Australia) and ANVISA (Brazil) for its manufacturing facility in Kandla SEZ
Drug Approval | December 17, 2024

Rusan Pharma achieves GMP approvals from TGA (Australia) and ANVISA (Brazil) for its manufacturing facility in Kandla SEZ

The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market


Merck announces FDA acceptance of biologics license application for Clesrovimab
Drug Approval | December 17, 2024

Merck announces FDA acceptance of biologics license application for Clesrovimab

An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season


Gilead Sciences appoints Dietmar Berger as Chief Medical Officer
People | December 14, 2024

Gilead Sciences appoints Dietmar Berger as Chief Medical Officer

Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines


Pfizer announces Phase 3 PATINA study in patients with HR+, HER2+ metastatic breast cancer
News | December 13, 2024

Pfizer announces Phase 3 PATINA study in patients with HR+, HER2+ metastatic breast cancer

IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy


Arvinas and Pfizer presents phase 1b data from the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
Diagnostic Center | December 11, 2024

Arvinas and Pfizer presents phase 1b data from the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate


Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody
Diagnostic Center | December 10, 2024

Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody

Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma


LVMH Recherche and Integrated Biosciences partner to discover anti-aging chemical entities
News | December 10, 2024

LVMH Recherche and Integrated Biosciences partner to discover anti-aging chemical entities

Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging